JP4035589B2 - 修飾バックボーンを有するアンチセンスプローブと核酸の液中ハイブリッド形成 - Google Patents
修飾バックボーンを有するアンチセンスプローブと核酸の液中ハイブリッド形成 Download PDFInfo
- Publication number
- JP4035589B2 JP4035589B2 JP2000551045A JP2000551045A JP4035589B2 JP 4035589 B2 JP4035589 B2 JP 4035589B2 JP 2000551045 A JP2000551045 A JP 2000551045A JP 2000551045 A JP2000551045 A JP 2000551045A JP 4035589 B2 JP4035589 B2 JP 4035589B2
- Authority
- JP
- Japan
- Prior art keywords
- probe
- nucleobase
- backbone
- antisense probe
- target sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000523 sample Substances 0.000 title claims description 200
- 238000009396 hybridization Methods 0.000 title claims description 63
- 230000000692 anti-sense effect Effects 0.000 title claims description 40
- 150000007523 nucleic acids Chemical class 0.000 title description 11
- 102000039446 nucleic acids Human genes 0.000 title description 10
- 108020004707 nucleic acids Proteins 0.000 title description 10
- 239000007788 liquid Substances 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 64
- 239000012530 fluid Substances 0.000 claims description 27
- 239000002773 nucleotide Substances 0.000 claims description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 27
- 239000003550 marker Substances 0.000 claims description 20
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 13
- 150000004713 phosphodiesters Chemical class 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 230000001678 irradiating effect Effects 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical group 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 102000053602 DNA Human genes 0.000 description 29
- 108091093037 Peptide nucleic acid Proteins 0.000 description 20
- 230000000295 complement effect Effects 0.000 description 20
- 108091034117 Oligonucleotide Proteins 0.000 description 15
- 230000000171 quenching effect Effects 0.000 description 14
- 238000002189 fluorescence spectrum Methods 0.000 description 13
- 239000003298 DNA probe Substances 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 108020003215 DNA Probes Proteins 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000005284 excitation Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000002751 oligonucleotide probe Substances 0.000 description 8
- 238000001917 fluorescence detection Methods 0.000 description 7
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000008051 TBE buffer Substances 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- -1 phosphate modified oligonucleotides Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000009987 spinning Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000002787 antisense oligonuctleotide Substances 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001444 catalytic combustion detection Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QQVDJLLNRSOCEL-UHFFFAOYSA-N (2-aminoethyl)phosphonic acid Chemical class [NH3+]CCP(O)([O-])=O QQVDJLLNRSOCEL-UHFFFAOYSA-N 0.000 description 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101150104425 T4 gene Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- PREFYZZMLJYIQN-UHFFFAOYSA-N aminophosphanyloxymethane Chemical compound COPN PREFYZZMLJYIQN-UHFFFAOYSA-N 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- GTTBQSNGUYHPNK-UHFFFAOYSA-N hydroxymethylphosphonic acid Chemical class OCP(O)(O)=O GTTBQSNGUYHPNK-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- XDROKJSWHURZGO-UHFFFAOYSA-N isopsoralen Natural products C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- MZDMEAKVGTZHES-UHFFFAOYSA-N methylphosphonamidous acid Chemical compound CP(N)O MZDMEAKVGTZHES-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ZORAAXQLJQXLOD-UHFFFAOYSA-N phosphonamidous acid Chemical compound NPO ZORAAXQLJQXLOD-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/083,410 | 1998-05-22 | ||
| US09/083,410 US6046004A (en) | 1997-02-27 | 1998-05-22 | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| PCT/IB1999/000909 WO1999061665A2 (en) | 1998-05-22 | 1999-05-20 | Solution hybridization of nucleic acids with antisense probes having modified backbones |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002516667A JP2002516667A (ja) | 2002-06-11 |
| JP2002516667A5 JP2002516667A5 (https=) | 2005-11-17 |
| JP4035589B2 true JP4035589B2 (ja) | 2008-01-23 |
Family
ID=22178135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000551045A Expired - Fee Related JP4035589B2 (ja) | 1998-05-22 | 1999-05-20 | 修飾バックボーンを有するアンチセンスプローブと核酸の液中ハイブリッド形成 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6046004A (https=) |
| EP (1) | EP1078101A2 (https=) |
| JP (1) | JP4035589B2 (https=) |
| AU (1) | AU3724499A (https=) |
| WO (1) | WO1999061665A2 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403313B1 (en) * | 1999-12-21 | 2002-06-11 | Ingeneus Corporation | Fluorescent intensity assay for duplex and triplex nucleic acid hybridization solution utilizing fluorescent intercalators |
| US6420115B1 (en) * | 1999-12-21 | 2002-07-16 | Ingeneus Corporation | Cation mediated triplex hybridization assay |
| US6656692B2 (en) | 1999-12-21 | 2003-12-02 | Ingeneus Corporation | Parallel or antiparallel, homologous or complementary binding of nucleic acids or analogues thereof to form duplex, triplex or quadruplex complexes |
| US6858390B2 (en) | 1998-12-31 | 2005-02-22 | Ingeneus Corporation | Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| US6911536B1 (en) | 1999-12-21 | 2005-06-28 | Ingeneus Corporation | Triplex and quadruplex catalytic hybridization |
| US7309569B2 (en) | 1999-12-21 | 2007-12-18 | Ingeneus, Inc. | Parallel or antiparallel, homologous or complementary binding of nucleic acids or analogues thereof to form duplex, triplex or quadruplex complexes |
| US7052844B2 (en) * | 1999-12-21 | 2006-05-30 | Ingeneus, Inc. | Purification of DS-DNA using heteropolymeric capture probes and a triplex, quadruplex or homologous duplex binding mechanism |
| US6927027B2 (en) | 1999-12-21 | 2005-08-09 | Ingeneus Corporation | Nucleic acid multiplex formation |
| US20030181412A1 (en) * | 1999-12-21 | 2003-09-25 | Ingeneus Corporation | Method for modifying transcription and/or translation in an organism for therapeutic, prophylactic and/or analytic uses |
| US6924108B2 (en) | 1999-12-21 | 2005-08-02 | Ingeneus Corporation | Nucleic acid binding enhancement by conjugation with nucleotides, nucleosides, bases and/or their analogues |
| US7220541B2 (en) | 2000-01-24 | 2007-05-22 | Ingeneus, Inc. | Homogeneous assay of biopolymer binding by means of multiple measurements under varied conditions |
| US20030170659A1 (en) * | 2000-01-24 | 2003-09-11 | Ingeneus Corporation | Electrical treatment of binding media to encourage, discourage and/or study biopolymer binding |
| US6613524B1 (en) | 2000-01-24 | 2003-09-02 | Ingeneus Corporation | Amperometric affinity assay and electrically stimulated complexes of nucleic acids |
| US6982147B2 (en) * | 2000-01-24 | 2006-01-03 | Ingeneus Corporation | Apparatus for assaying biopolymer binding by means of multiple measurements under varied conditions |
| WO2001098537A2 (en) * | 2000-06-17 | 2001-12-27 | Third Wave Technologies, Inc. | Nucleic acid accessible hybridization sites |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| EP1392853B1 (en) * | 2000-08-30 | 2006-04-26 | Avi Biopharma, Inc. | Method for analysis of oligonucleotide analogs |
| EP1326892A2 (en) | 2000-10-12 | 2003-07-16 | University of Rochester | Compositions that inhibit proliferation of cancer cells |
| DE10155031A1 (de) * | 2001-11-09 | 2003-05-28 | Friz Biochem Gmbh | Fluoreszenz-Quenchen zur Detektion von Ligat-Ligand Assoziationsereignissen in elektrischen Feldern |
| EP1572168B1 (en) | 2002-02-06 | 2010-05-26 | Vicor Technologies, Inc. | Anti-infarction molecules |
| AU2003253580A1 (en) * | 2002-02-26 | 2003-11-17 | University Of Minnesota | Variants of nedd4l associated with hypertension and viral budding |
| AU2003257181A1 (en) | 2002-08-05 | 2004-02-23 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
| US20040180345A1 (en) * | 2003-03-14 | 2004-09-16 | Ingeneus Corporation | Pre-incubation method to improve signal/noise ratio of nucleic acid assays |
| CA2544476A1 (en) * | 2003-12-12 | 2005-06-23 | Infectio Recherche Inc. | System for charge-based detection of nucleic acids |
| US8029815B2 (en) * | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
| SG155995A1 (en) * | 2004-09-24 | 2009-10-29 | Ingeneus Inc | Genomic assay |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| US7476733B2 (en) * | 2005-03-25 | 2009-01-13 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease |
| EP2392647A1 (en) | 2005-10-14 | 2011-12-07 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
| US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| EP3034083B1 (en) | 2006-09-21 | 2020-12-09 | University of Rochester | Antisense oligonucleotides for use in treating myotonic dystrophy |
| US8999317B2 (en) | 2006-11-01 | 2015-04-07 | University Of Rochester | Methods and compositions related to the structure and function of APOBEC3G |
| KR20090089462A (ko) | 2006-12-11 | 2009-08-21 | 유니버시티 오브 유타 리써치 파운데이션 | 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법 |
| EP2030615A3 (en) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
| US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| WO2010070380A2 (en) | 2007-12-03 | 2010-06-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health | Doc1 compositions and methods for treating cancer |
| US20110262395A1 (en) | 2008-05-08 | 2011-10-27 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
| CA2734322A1 (en) * | 2008-08-15 | 2010-02-18 | Georgetown University | Na channels, disease, and related assays and compositions |
| US20120070443A1 (en) | 2008-12-02 | 2012-03-22 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
| WO2011031974A1 (en) | 2009-09-10 | 2011-03-17 | Southern Research Institute | Acridine analogs in the treatment of gliomas |
| US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| US9970002B2 (en) | 2012-12-12 | 2018-05-15 | Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
| EP3071590A4 (en) | 2013-11-21 | 2017-07-19 | SeNA Research, Inc. | Methods for structural determination of selenium derivatized nucleic acid complexes |
| AU2015220749B2 (en) | 2014-02-21 | 2020-12-24 | Ventana Medical Systems, Inc. | Single-stranded oligonucleotide probes for chromosome or gene copy enumeration |
| MX383117B (es) | 2014-07-31 | 2025-03-13 | Anji Pharmaceuticals Inc | Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma. |
| US20170016051A1 (en) * | 2015-07-15 | 2017-01-19 | Orizhan Bioscience Limited | DNA Methylation Detection |
| JP7556688B2 (ja) | 2016-07-28 | 2024-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｇｐｒ１５６変異体及びその使用 |
| AU2017306422A1 (en) | 2016-08-03 | 2019-01-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TLR9 targeted therapeutics |
| IL314915B1 (en) | 2017-01-23 | 2026-02-01 | Regeneron Pharma | Variants of 17-beta-hydroxysteroid dehydrogenase and their uses |
| MX2019014661A (es) | 2017-06-05 | 2020-07-29 | Regeneron Pharma | Variantes de b4galt1 y usos de estas. |
| CA3074652A1 (en) | 2017-09-06 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof |
| JP2020536500A (ja) | 2017-09-07 | 2020-12-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 溶質キャリアファミリー１４メンバー１（ｓｌｃ１４ａ１）の変異型及びその使用 |
| WO2019051355A1 (en) | 2017-09-08 | 2019-03-14 | Ohio State Innovation Foundation | NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS |
| US10961583B2 (en) | 2017-10-11 | 2021-03-30 | Regeneron Phramaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
| EP3697807A1 (en) | 2017-10-16 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Cornulin (crnn) variants and uses thereof |
| CN112930404A (zh) * | 2018-09-05 | 2021-06-08 | 瑞德库尔有限责任公司 | 用于治疗剂分析的方法和系统 |
| WO2020076976A1 (en) | 2018-10-10 | 2020-04-16 | Readcoor, Inc. | Three-dimensional spatial molecular indexing |
| EP3994125B1 (en) | 2019-07-02 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Modulators of hsd17b13 and methods of use thereof |
| WO2021155063A1 (en) | 2020-01-29 | 2021-08-05 | Readcoor, Llc | Compositions and methods for analyte detection |
| US20220049303A1 (en) | 2020-08-17 | 2022-02-17 | Readcoor, Llc | Methods and systems for spatial mapping of genetic variants |
| WO2024173343A1 (en) | 2023-02-14 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Compounds targeting hydroxysteroid 17-beta dehydrogenase (hsd17b) and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4220450A (en) * | 1978-04-05 | 1980-09-02 | Syva Company | Chemically induced fluorescence immunoassay |
| US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5166330A (en) * | 1983-09-06 | 1992-11-24 | Hoechst Aktiengesellschaft | Process for the preparation of nucleoside alkyl-aralkyl- and aryl-phosphonites and -phosphonates |
| FR2558172B1 (fr) * | 1984-01-16 | 1986-06-13 | Inst Nat Sante Rech Med | Sonde contenant un acide nucleique modifie et reconnaissance par des anticorps specifiques et utilisation de cette sonde et de ces anticorps specifiques pour detecter et caracteriser une sequence d'adn homologue |
| JP3022967B2 (ja) * | 1985-03-15 | 2000-03-21 | アンチバイラルズ インコーポレイテッド | 立体規則性ポリヌクレオチド結合ポリマー |
| US5470974A (en) * | 1985-03-15 | 1995-11-28 | Neu-Gene Development Group | Uncharged polynucleotide-binding polymers |
| US5217866A (en) * | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5166315A (en) * | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5405938A (en) * | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5521063A (en) * | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5217592A (en) * | 1985-09-26 | 1993-06-08 | Jones Kenneth W | Electrophoresis and vacuum molecular transfer apparatus |
| US5501949A (en) * | 1985-12-10 | 1996-03-26 | Murex Diagnostics Corporation | Particle bound binding component immunoassay |
| EP0232967B1 (en) * | 1986-01-10 | 1993-04-28 | Amoco Corporation | Competitive homogeneous assay |
| US5310650A (en) * | 1986-09-29 | 1994-05-10 | Abbott Laboratoires | Method and device for improved reaction kinetics in nucleic acid hybridizations |
| US4787963A (en) * | 1987-05-04 | 1988-11-29 | Syntro Corporation | Method and means for annealing complementary nucleic acid molecules at an accelerated rate |
| US5100775A (en) * | 1988-03-16 | 1992-03-31 | Smyczek Peter J | Method for conducting nucleic acid hybridization in chamber with precise fluid delivery |
| CA1337639C (en) * | 1989-08-01 | 1995-11-28 | Joseph Eugene Celebuski | Dna probe assay using neutrally charged probe strands |
| US5623065A (en) * | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
| US5459255A (en) * | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5618704A (en) * | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
| US5677437A (en) * | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5223618A (en) * | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| US5610289A (en) * | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US5541307A (en) * | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5602240A (en) * | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| EP0533906A4 (en) * | 1991-04-11 | 1994-09-28 | Baxter Diagnostics Inc | Detection of dna/rna by fluorescence polarization |
| US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5632957A (en) * | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
| US5332659A (en) * | 1992-04-09 | 1994-07-26 | The United States Of America As Represented By The Secretary Of The Navy | Light emission-or absorbance-based binding assays for polynucleic acids |
| DE4216949C2 (de) * | 1992-05-22 | 1997-07-24 | Christoph Prof Dr Dr Cremer | Nichtenzymatisches Verfahren zur In-situ-Hybridisierung bei spezifischen Proben |
| US5674698A (en) * | 1992-09-14 | 1997-10-07 | Sri International | Up-converting reporters for biological and other assays using laser excitation techniques |
| US5503980A (en) * | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| JP3789471B2 (ja) * | 1993-07-19 | 2006-06-21 | ジェン−プローブ・インコーポレイテッド | オリゴヌクレオチドスクリーニングアッセイ |
| US5538848A (en) * | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5723288A (en) * | 1994-05-06 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans, and kits useful therefor |
| US5747247A (en) * | 1994-07-25 | 1998-05-05 | The Regents Of The University Of California | Spectroscopic helicase assay |
| JPH11512617A (ja) * | 1995-10-06 | 1999-11-02 | パーセプテイブ・バイオシステムズ・インコーポレイテツド | ペプチド核酸プローブを用いるハイブリダイゼーション分析のための方法、装置及びキット |
| US5846729A (en) * | 1997-02-27 | 1998-12-08 | Lorne Park Research, Inc. | Assaying nucleotides in solution using a fluorescent intensity quenching effect |
| JP4110223B2 (ja) * | 1997-02-27 | 2008-07-02 | インジェネウス・インコーポレーテッド | Ｐｎａプローブを用いる、溶液中でのヌクレオチドアッセイ法 |
-
1998
- 1998-05-22 US US09/083,410 patent/US6046004A/en not_active Expired - Fee Related
-
1999
- 1999-05-20 WO PCT/IB1999/000909 patent/WO1999061665A2/en not_active Ceased
- 1999-05-20 JP JP2000551045A patent/JP4035589B2/ja not_active Expired - Fee Related
- 1999-05-20 EP EP99919462A patent/EP1078101A2/en not_active Withdrawn
- 1999-05-20 AU AU37244/99A patent/AU3724499A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999061665A2 (en) | 1999-12-02 |
| US6046004A (en) | 2000-04-04 |
| EP1078101A2 (en) | 2001-02-28 |
| JP2002516667A (ja) | 2002-06-11 |
| WO1999061665A3 (en) | 2000-01-27 |
| AU3724499A (en) | 1999-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4035589B2 (ja) | 修飾バックボーンを有するアンチセンスプローブと核酸の液中ハイブリッド形成 | |
| US5846729A (en) | Assaying nucleotides in solution using a fluorescent intensity quenching effect | |
| US6060242A (en) | PNA diagnostic methods | |
| EP1078100B1 (en) | Quantitative method for detecting nucleotide concentration | |
| ES2352417T3 (es) | Método para la detección de una alteración en un ácido nucléico. | |
| EP0975800B1 (en) | Assaying nucleotides in solution using pna probes | |
| KR20160003814A (ko) | 순차적 하이브리드화 바코딩에 의한 분자의 멀티플렉스 표지화 | |
| JPH09107996A (ja) | 検出可能にラベルされた二元的形態、オリゴヌクレオチドプローブ、アッセイおよびキット | |
| JP2007050010A (ja) | アレイ利用型核酸ハイブリダイゼーションのための新規な組成物および方法 | |
| KR20110025993A (ko) | 단일-분자 전체 게놈 분석용 장치 및 방법 | |
| JP3495752B2 (ja) | 生標的個体の検出方法およびプローブ | |
| US20090130650A1 (en) | Methods for the production of highly sensitive and specific cell surface probes | |
| JP5663491B2 (ja) | 標的核酸の検出方法 | |
| JPH08510910A (ja) | ヒトゲノムの延長ヌクレオチド反復配列の直接検出 | |
| KR20190020133A (ko) | 염색체에 대한 인-시츄 혼성화를 위한 dna 탐침 | |
| JP4541731B2 (ja) | 核酸検出方法 | |
| WO2005028647A1 (ja) | 核酸プローブ、核酸チップ、標的核酸検出方法、薬剤スクリーニング方法、標的核酸検出装置及び遺伝子診断方法 | |
| CN118265800A (zh) | 用于多路fish的比率计量符号与顺序编码 | |
| JPH11178600A (ja) | 標的核酸検出プローブ | |
| JPH0484751A (ja) | 遺伝子の検出方法 | |
| JP2013135679A (ja) | 分子的認識によって作用する新規な検出プローブ | |
| JP2004089092A (ja) | ヒトチトクロムｐ４５０２ｃ１９遺伝子の点突然変異の検出用核酸及びそれを用いたヒトチトクロムｐ４５０２ｃ１９遺伝子の点突然変異の検出方法 | |
| JP2008199904A (ja) | ラットにおけるストレス関連の蛋白質をコードするｍＲＮＡの測定方法、そのためのプローブ及びキット | |
| JP2002101900A (ja) | ヒトにおけるアセチル抱合に関与する酵素の測定方法、そのためのプローブ及びキット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040412 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040412 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040916 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070510 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070810 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070904 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20071002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071003 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071002 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101109 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |